Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Clin Cancer Res. 2021 Oct 13;28(1):201–214. doi: 10.1158/1078-0432.CCR-21-1248

Figure 5. OV-αmCD47-G2b is efficacious to treat ovarian cancer in an immunocompetent metastasis mouse model.

Figure 5.

(A) Inhibition of anti-mouse CD47 mAb binding by αmCD47-G2b mAb. ID8 cells were incubated with different concentrations of unlabeled αmCD47-G2b, followed by flow cytometry post incubation with a conjugated anti-mouse CD47. (B) Mouse macrophage phagocytosis induced by conditioned media from OV-αmCD47-G2b-, OV-αmCD47-G3- or OV-Q1-infected cells targeting ID8 cells, as measured by flow cytometry. (C) Cytotoxicity of mouse primary NK cells against ID8 cells that were treated with conditioned media from OV-αmCD47-G2b-, OV-αmCD47-G3- or OV-Q1-infected cells, as measured by 51Cr release. OV-Q1 vs. OV-αmCD47-G2b, ***P ≤ 0.001; OV-αmCD47-G2b vs. OV-αmCD47-G3, ***P ≤ 0.001. (D) Survival of ID8 tumor-bearing mice treated with OV-Q1, OV-αmCD47-G2b, OV-αmCD47-G3, or vehicle control (n=6 mice each group). (E) ID8 ovarian tumor mice were treated with OV-Q1 or OV-αmCD47-G2b with or without NK cell depletion. P < 0.05 for OV- αmCD47-G2b without NK cell depletion vs. OV-αmCD47-G2b with NK cell depletion. (F) ID8 ovarian tumor mice were treated with OV-Q1 or OV-αmCD47-G2b with or without macrophage depletion. P ≤ 0.01 for αmCD47-G2b without macrophage depletion vs. αmCD47-G2b with macrophage depletion. Survival was estimated by the Kaplan–Meier method and compared by log-rank test (n=6 mice each group). For B, statistical analyses were performed by one-way ANOVA with P values corrected for multiple comparisons by Bonferroni method (n = 3 mice). *P ≤ 0.05; **P ≤ 0.01; ***P ≤0.001; ****P ≤ 0.0001. Data were presented as mean values +/− SD.